Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Large B-Cell, Diffuse | 11 | 2024 | 1378 | 2.350 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 15 | 2024 | 1596 | 1.660 |
Why?
|
Lymphoma, Follicular | 3 | 2022 | 435 | 1.100 |
Why?
|
Immunotherapy, Adoptive | 11 | 2024 | 1270 | 0.920 |
Why?
|
Antibodies, Bispecific | 2 | 2022 | 164 | 0.910 |
Why?
|
Antigens, CD19 | 7 | 2023 | 380 | 0.800 |
Why?
|
Mucin-1 | 6 | 2017 | 543 | 0.600 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2540 | 0.590 |
Why?
|
Antineoplastic Agents | 9 | 2022 | 13695 | 0.580 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2015 | 693 | 0.500 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 93 | 0.480 |
Why?
|
Vidarabine | 4 | 2024 | 345 | 0.460 |
Why?
|
Purines | 4 | 2021 | 594 | 0.440 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2020 | 260 | 0.390 |
Why?
|
Immunoglobulin A | 2 | 2012 | 992 | 0.380 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11524 | 0.370 |
Why?
|
Antibodies, Neoplasm | 1 | 2011 | 286 | 0.340 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 233 | 0.330 |
Why?
|
B-Lymphocytes | 2 | 2022 | 4665 | 0.320 |
Why?
|
Dendritic Cells | 3 | 2017 | 2725 | 0.320 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1537 | 0.290 |
Why?
|
T-Lymphocytes | 9 | 2023 | 10180 | 0.290 |
Why?
|
Adenine | 5 | 2024 | 936 | 0.270 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2023 | 5442 | 0.270 |
Why?
|
Quinazolinones | 2 | 2019 | 221 | 0.270 |
Why?
|
Thrombocytopenia | 4 | 2022 | 1179 | 0.260 |
Why?
|
Lymphoma, B-Cell | 2 | 2022 | 931 | 0.250 |
Why?
|
Vaccination | 2 | 2016 | 3278 | 0.240 |
Why?
|
Remission Induction | 4 | 2021 | 2386 | 0.240 |
Why?
|
Multiple Myeloma | 4 | 2017 | 5181 | 0.240 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 207 | 0.240 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2018 | 437 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.230 |
Why?
|
Piperidines | 5 | 2024 | 1602 | 0.220 |
Why?
|
Isoquinolines | 2 | 2021 | 367 | 0.220 |
Why?
|
Pyrazoles | 5 | 2020 | 1972 | 0.220 |
Why?
|
Cyclophosphamide | 4 | 2024 | 2242 | 0.220 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2022 | 1381 | 0.210 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2023 | 3523 | 0.210 |
Why?
|
Antibodies, Monoclonal | 4 | 2016 | 9274 | 0.200 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2023 | 220 | 0.200 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 2957 | 0.200 |
Why?
|
Neutropenia | 2 | 2024 | 895 | 0.190 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 60 | 0.190 |
Why?
|
Chromosome Deletion | 2 | 2018 | 1401 | 0.180 |
Why?
|
Pyrimidines | 4 | 2020 | 2942 | 0.180 |
Why?
|
Sulfonamides | 2 | 2021 | 1938 | 0.180 |
Why?
|
Leukemia, Prolymphocytic, B-Cell | 1 | 2019 | 1 | 0.180 |
Why?
|
Cancer Vaccines | 3 | 2017 | 1023 | 0.170 |
Why?
|
Antigens, Neoplasm | 3 | 2017 | 1988 | 0.170 |
Why?
|
Vinblastine | 1 | 2019 | 502 | 0.150 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 142 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 5172 | 0.150 |
Why?
|
Humans | 52 | 2024 | 744343 | 0.150 |
Why?
|
Dacarbazine | 1 | 2019 | 566 | 0.140 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2018 | 233 | 0.140 |
Why?
|
Quinoxalines | 1 | 2018 | 290 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9239 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1379 | 0.130 |
Why?
|
Signal Transduction | 3 | 2017 | 23403 | 0.130 |
Why?
|
Azacitidine | 1 | 2017 | 347 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1230 | 0.130 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 91 | 0.130 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2017 | 548 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1526 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 3 | 2019 | 5535 | 0.120 |
Why?
|
Transplantation, Homologous | 4 | 2018 | 4776 | 0.120 |
Why?
|
Autoimmunity | 1 | 2021 | 1349 | 0.120 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 651 | 0.110 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2124 | 0.110 |
Why?
|
Cell Proliferation | 4 | 2017 | 10481 | 0.110 |
Why?
|
Cell Communication | 2 | 2017 | 1621 | 0.110 |
Why?
|
Doxorubicin | 1 | 2019 | 2234 | 0.110 |
Why?
|
Aged | 17 | 2024 | 163280 | 0.110 |
Why?
|
Aged, 80 and over | 11 | 2024 | 57776 | 0.110 |
Why?
|
Apoptosis | 4 | 2017 | 9727 | 0.100 |
Why?
|
Peptides | 2 | 2015 | 4409 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2019 | 2948 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1355 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1415 | 0.100 |
Why?
|
Bone Marrow | 2 | 2020 | 2948 | 0.090 |
Why?
|
Middle Aged | 18 | 2024 | 213383 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2017 | 7913 | 0.090 |
Why?
|
Hemorrhage | 2 | 2020 | 3461 | 0.090 |
Why?
|
Platelet Count | 1 | 2012 | 781 | 0.090 |
Why?
|
Recurrence | 3 | 2022 | 8340 | 0.080 |
Why?
|
Coculture Techniques | 3 | 2017 | 1341 | 0.080 |
Why?
|
Receptors, Interleukin-6 | 1 | 2010 | 224 | 0.080 |
Why?
|
Oxidative Stress | 2 | 2017 | 3086 | 0.080 |
Why?
|
Standard of Care | 2 | 2022 | 564 | 0.080 |
Why?
|
Anemia, Aplastic | 1 | 2010 | 226 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2015 | 1275 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2017 | 2455 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2020 | 4479 | 0.080 |
Why?
|
Treatment Outcome | 11 | 2024 | 63114 | 0.080 |
Why?
|
Thrombopoiesis | 1 | 2008 | 153 | 0.070 |
Why?
|
Adult | 13 | 2024 | 214055 | 0.070 |
Why?
|
Up-Regulation | 2 | 2017 | 4217 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 890 | 0.070 |
Why?
|
Immunoglobulin Isotypes | 1 | 1987 | 158 | 0.070 |
Why?
|
Antigen Presentation | 1 | 2012 | 1284 | 0.070 |
Why?
|
Rheumatoid Factor | 1 | 1987 | 188 | 0.070 |
Why?
|
Lymphocyte Activation | 4 | 2021 | 5524 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2012 | 1607 | 0.070 |
Why?
|
Treatment Failure | 1 | 2012 | 2618 | 0.070 |
Why?
|
Survival Analysis | 4 | 2020 | 10252 | 0.070 |
Why?
|
Female | 21 | 2022 | 380194 | 0.070 |
Why?
|
Mice, SCID | 3 | 2016 | 2716 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1376 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 659 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4149 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11031 | 0.060 |
Why?
|
Europe | 1 | 2021 | 3339 | 0.060 |
Why?
|
Anticoagulants | 1 | 2020 | 4599 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39050 | 0.060 |
Why?
|
Male | 20 | 2022 | 350118 | 0.060 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 973 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6895 | 0.060 |
Why?
|
MicroRNAs | 2 | 2017 | 3752 | 0.060 |
Why?
|
Medicare | 1 | 2022 | 6566 | 0.060 |
Why?
|
Cell Line, Tumor | 5 | 2017 | 16689 | 0.060 |
Why?
|
Animals | 10 | 2020 | 168757 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2017 | 3557 | 0.060 |
Why?
|
Bone Resorption | 1 | 1987 | 723 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2016 | 2988 | 0.060 |
Why?
|
Polydeoxyribonucleotides | 1 | 2023 | 127 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29063 | 0.050 |
Why?
|
United States | 3 | 2023 | 69872 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4933 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 1620 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
Intestines | 1 | 2010 | 1924 | 0.050 |
Why?
|
Mutation | 3 | 2020 | 29786 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2010 | 1580 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1799 | 0.050 |
Why?
|
Young Adult | 6 | 2024 | 56430 | 0.050 |
Why?
|
Leukapheresis | 1 | 2020 | 131 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12788 | 0.050 |
Why?
|
Clone Cells | 1 | 2023 | 1692 | 0.040 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1878 | 0.040 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 212 | 0.040 |
Why?
|
Mice | 8 | 2020 | 81183 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 38 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6234 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2017 | 2077 | 0.040 |
Why?
|
Chronic Disease | 3 | 2023 | 9146 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 930 | 0.040 |
Why?
|
Cross-Priming | 1 | 2017 | 82 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1866 | 0.040 |
Why?
|
Perforin | 1 | 2017 | 168 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 387 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4751 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 286 | 0.040 |
Why?
|
Blotting, Western | 2 | 2015 | 5179 | 0.040 |
Why?
|
Cisplatin | 1 | 2022 | 1662 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 847 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 631 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5686 | 0.030 |
Why?
|
Safety | 1 | 2020 | 1186 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2274 | 0.030 |
Why?
|
Receptors, Antigen | 1 | 2015 | 53 | 0.030 |
Why?
|
Ribonuclease III | 1 | 2017 | 275 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Isoantigens | 1 | 2017 | 567 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 307 | 0.030 |
Why?
|
Dexamethasone | 1 | 2022 | 1951 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 141 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7322 | 0.030 |
Why?
|
NADP | 1 | 2015 | 226 | 0.030 |
Why?
|
Adolescent | 4 | 2024 | 85781 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1348 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15540 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2019 | 1850 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3271 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2017 | 1369 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 528 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 5974 | 0.030 |
Why?
|
Immunomodulation | 1 | 2017 | 541 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2015 | 431 | 0.030 |
Why?
|
Prednisone | 1 | 2018 | 1574 | 0.030 |
Why?
|
Incidence | 1 | 2021 | 20947 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 589 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 873 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 1792 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 2187 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 1987 | 3712 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18370 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 3913 | 0.020 |
Why?
|
Biological Products | 1 | 2020 | 860 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2013 | 657 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 987 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 805 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 25043 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1643 | 0.020 |
Why?
|
Anemia | 1 | 2020 | 1506 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1783 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1538 | 0.020 |
Why?
|
Infant | 1 | 2012 | 35136 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 1836 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1622 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1157 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 21683 | 0.020 |
Why?
|
Child, Preschool | 1 | 2012 | 41006 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2015 | 13033 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2017 | 3206 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1682 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2107 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2013 | 1880 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12354 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2017 | 11483 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4554 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6314 | 0.020 |
Why?
|
Benzoates | 1 | 2008 | 217 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2649 | 0.020 |
Why?
|
Hydrazines | 1 | 2008 | 226 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2008 | 225 | 0.020 |
Why?
|
Arthrography | 1 | 1987 | 149 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8642 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2017 | 3586 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.020 |
Why?
|
Receptors, Fc | 1 | 2008 | 541 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2915 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2012 | 1838 | 0.010 |
Why?
|
Child | 1 | 2012 | 77709 | 0.010 |
Why?
|
Gene Expression | 1 | 2017 | 7799 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2133 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9648 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10638 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8428 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7474 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2008 | 3772 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40075 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6756 | 0.010 |
Why?
|
Hepatitis C | 1 | 2008 | 1591 | 0.010 |
Why?
|
Blood Platelets | 1 | 2008 | 2508 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 21746 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 12072 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2008 | 5021 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2015 | 77449 | 0.010 |
Why?
|